secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuraxis, INC (NRXS)
CIK:        0001933567
Form:       8-K
Filed at:   2023-08-17T23:59:59+00:00
Accession:  0001493152-23-029326
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeurAxis reports over $8M in cumulative IB-Stim revenue through March 31, 2023
------------------------------------------------------------------------------

- Over $8M in revenue from IB-Stim since commercial launch after FDA clearance for pediatric functional abdominal pain and IBS.
- Approximately $2M of total revenue was generated in 2019 and 2020.
- Company is conducting clinical trials for four additional pediatric indications: chronic nausea, post-concussion syndrome, chemo-induced nausea, and cyclic vomiting.
- CEO Brian Carrico cites growing adoption, non-drug therapy trend, and recently completed IPO funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933567/000149315223029326/0001493152-23-029326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933567/000149315223029326/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-029326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer